M

MiMedx Group
D

MDXG

7.97000
USD
0.13
(1.66%)
مغلق
حجم التداول
21,045
الربح لكل سهم
1
العائد الربحي
-
P/E
14
حجم السوق
1,171,161,318
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    A
    -1.400
    (-1.02%)
    135.400 USD
    A
    ALGN
    -7.520
    (-3.80%)
    190.370 USD
    BSX
    BSX
    -0.840
    (-0.80%)
    104.480 USD
    EW
    EW
    -1.380
    (-1.85%)
    73.300 USD
    ILMN
    ILMN
    -3.080
    (-3.17%)
    94.180 USD
    I
    IRWD
    -0.09500
    (-4.99%)
    1.81000 USD
    M
    MTD
    -16.62
    (-1.28%)
    1,286.54 USD
    O
    OSIS
    -12.480
    (-5.81%)
    202.240 USD
    X
    XRAY
    -0.200
    (-1.06%)
    18.740 USD
    ZBH
    ZBH
    1.250
    (1.21%)
    104.890 USD
    المزيد
الأخبار
المقالات

العنوان: MiMedx Group

القطاع: Healthcare
الصناعة: Biotechnology
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.